Neurocrine Biosciences Announces Publication of Expert Perspectives on Hyperphagia in Prader-Willi Syndrome

Neurocrine Biosciences Presents New Research on Clinically Meaningful Health Improvements in Tardive Dyskinesia Patients

Neurocrine Biosciences announced new research establishing a 6-point improvement on the EQ Visual Analogue Scale as a benchmark for clinically meaningful change in patients with tardive dyskinesia treated with INGREZZA.

Neurocrine Biosciences shares are trading higher after the company announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer's disease.

Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease.